Literature DB >> 27356182

Small cell undifferentiated (SCUD) hepatoblastomas: All malignant rhabdoid tumors?

Christian Vokuhl1, Florian Oyen2, Beate Häberle3, Dietrich von Schweinitz3, Reinhard Schneppenheim2, Ivo Leuschner4.   

Abstract

Small cell undifferentiated (SCUD) hepatoblastoma is a rare variant of hepatoblastoma with poor outcome and loss of INI1 expression, sharing this with malignant rhabdoid tumors (MRT). We studied all tumors from the files of the Kiel Pediatric Tumor Registry (KTR) with the initial diagnosis of SCUD and MRT. After re-review, we performed immunistochemistry, fluorescence in situ hybridization, and multiplex ligation dependent probe amplification for loss of expression and deletion of INI1/SMARCB1 in 23 tumors. Morphologically, 12 of the tumors had a small cell morphology, 9 showed the typical picture of MRT, and 2 were composed of both small cells and rhabdoid cells. All but 1 of the 23 tumors showed loss of INI1 protein expression by immunohistochemistry. Nineteen of the INI1 negative tumors were analyzed by FISH technique and all showed a deletion of the INI1/SMARCB1 gene (17 homozygous deletions, 2 heterozygous deletions). We investigated 14 of these cases by multiplex ligation dependent probe amplification and verified the deletions in all cases. In conclusion, we postulate that SCUD hepatoblastoma is not a hepatoblastoma but represents a malignant rhabdoid tumor of the liver.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27356182     DOI: 10.1002/gcc.22390

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

Review 1.  Hepatoblastoma: current knowledge and promises from preclinical studies.

Authors:  Diego F Calvisi; Antonio Solinas
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

2.  Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee.

Authors:  Angela Trobaugh-Lotrario; Howard M Katzenstein; Sarangarajan Ranganathan; Dolores Lopez-Terrada; Mark D Krailo; Jin Piao; Nadia Chung; Jessica Randazzo; Marcio H Malogolowkin; Wayne L Furman; Elizabeth B McCarville; Alexander J Towbin; Greg M Tiao; Stephen P Dunn; Max R Langham; Eugene D McGahren; James Feusner; Carlos Rodriguez-Galindo; Rebecka L Meyers; Allison F O'Neill; Milton J Finegold
Journal:  J Clin Oncol       Date:  2021-12-07       Impact factor: 44.544

3.  Expression of CD34 and β-Catenin in Malignant Rhabdoid Tumor of the Liver Mimicking Proximal-Type Epithelioid Sarcoma.

Authors:  Woo Cheal Cho; Fabiola Balarezo
Journal:  J Pathol Transl Med       Date:  2017-07-07

4.  TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia.

Authors:  Jenny Wegert; Christian Vokuhl; Barbara Ziegler; Karen Ernestus; Ivo Leuschner; Rhoikos Furtwängler; Norbert Graf; Manfred Gessler
Journal:  J Pathol Clin Res       Date:  2017-08-14

5.  Independent Assessment of the Children's Hepatic Tumors International Collaboration Risk Stratification for Hepatoblastoma and the Association of Tumor Histological Characteristics With Prognosis.

Authors:  Shengmei Zhou; Jemily Malvar; Yueh-Yun Chi; James Stein; Larry Wang; Yuri Genyk; Richard Sposto; Leo Mascarenhas
Journal:  JAMA Netw Open       Date:  2022-02-01

Review 6.  Surgical Pathology Diagnostic Pitfalls of Hepatoblastoma.

Authors:  Finn Morgan Auld; Consolato M Sergi
Journal:  Int J Surg Pathol       Date:  2022-01-20       Impact factor: 1.358

Review 7.  A Systematic Review and Meta-Analysis of Malignant Rhabdoid and Small Cell Undifferentiated Liver Tumors: A Rational for a Uniform Classification.

Authors:  Juri Fuchs; Anastasia Murtha-Lemekhova; Markus Kessler; Fabian Ruping; Patrick Günther; Alexander Fichtner; Dominik Sturm; Katrin Hoffmann
Journal:  Cancers (Basel)       Date:  2022-01-06       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.